R
R. Mogulla
Publications - 6
Citations - 64
R. Mogulla is an academic researcher. The author has contributed to research in topics: Medicine & Immunogenicity. The author has an hindex of 4, co-authored 6 publications receiving 64 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
S. C. Thuluva,Vikram M. Paradkar,S. Gunneri,V. Yerroju,R. Mogulla,K. Turaga,Mahesh Kyasani,Senthil Kumar Manoharan,Guruprasad R. Medigeshi,J. Singh,Heena Shaman,Chandramani Singh,Venkateshwar Rao A +12 more
TL;DR: A randomised Phase-1/2 trial followed by a Phase-2 trial were conducted to assess the safety and immunogenicity of the COVID-19 vaccine Corbevax and select to an optimum formulation as discussed by the authors .
Posted ContentDOI
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies
S. C. Thuluva,Vikram M. Paradkar,Kiran K. Turaga,S. Gunneri,V. Yerroju,R. Mogulla,Mahesh Kyasani,Suresh Kumar Manoharan,Guruprasad R. Medigeshi,J. Singh,Heena Shaman,Chandramani Singh,V. Rao A +12 more
TL;DR: Corbevax was well tolerated with no observed safety concerns and neutralizing antibody titers were suggestive of high vaccine effectiveness compared with human convalescent plasma or protective thresholds observed during vaccine efficacy trials of other COVID-19 vaccines.
Journal ArticleDOI
Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study
S. C. Thuluva,Vikram M. Paradkar,S. Gunneri,V. Yerroju,R. Mogulla,Pothakamuri Venkata Suneetha,K. Turaga,Mahesh Kyasani,Senthil Kumar Manoharan,Srikanth Adabala,Aditya Sri Javvadi,Guruprasad R. Medigeshi,J. Singh,Heena Shaman,Akshay Binayke,Aymaan Zaheer,Amit Awasthi,Manish Narang,Pradeep Papanna Nanjappa,Niranjana S. Mahantshetti,Bishan Swarup Garg,Anil Kumar Pandey +21 more
TL;DR: In this article , a phase-2/3 prospective, randomised, double-blind, placebo-controlled study evaluating safety, reactogenicity, tolerability and immunogenicity of CORBEVAX™ vaccine in children and adolescents was conducted.
Immunogenic superiority and safety of Biological E CORBEVAX vaccine compared to COVISHIELD (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial
S. C. Thuluva,Vikram M. Paradkar,Kiran K. Turaga,S. Gunneri,V. Yerroju,R. Mogulla,V. S. Pothakamuri,Mahesh Kyasani,Suresh Kumar Manoharan,Sumalatha Adabala,A. S. Javvadi,Guruprasad R. Medigeshi,J. Singh,Heena Shaman,Akshay Binayke,Aymaan Zaheer,A. Awasrhi,Chandramani Singh,Indraneel Basu,Akash A Khobragade,A. Pandey +20 more
TL;DR: Safety findings revealed that CORBEVAX vaccine has excellent safety profile when tested in larger and older population, similar to Moderna and Astra-Zeneca vaccine Phase III studies.
Journal ArticleDOI
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
S. C. Thuluva,Vikram M. Paradkar,S. Gunneri,V. Yerroju,R. Mogulla,Pothakamuri Venkata Suneetha,K. Turaga,Mahesh Kyasani,Senthil Kumar Manoharan,Srikanth Adabala,Aditya Sri Javvadi,Guruprasad R. Medigeshi,J. Singh,Heena Shaman,Akshay Binayke,Aymaan Zaheer,Amit Awasthi,Chandramani Singh,Venkateshwar Rao A,Anil Kumar Pandey +19 more
TL;DR: In this article , a phase-3 prospective, single-blinded, randomized, active controlled study was conducted at 18 sites across India in 18-80-year-old subjects.